{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:16:57Z","timestamp":1793395017479,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100019492","name":"National Natural Science Foundation of China-China Academy of General Technology Joint Fund for Basic Research","doi-asserted-by":"crossref","award":["82171611, 81971376"],"award-info":[{"award-number":["82171611, 81971376"]}],"id":[{"id":"10.13039\/501100019492","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2022YFC2804300"],"award-info":[{"award-number":["2022YFC2804300"]}]},{"name":"Shanghai Science and Technology Commission Research Project","award":["21ZR14389001"],"award-info":[{"award-number":["21ZR14389001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-43901-1","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:51:20Z","timestamp":1773773480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CHD1L promotes testicular cancer progression through epigenetic activation of the CXCR6\/PI3K\/AKT pathway"],"prefix":"10.1038","volume":"16","author":[{"given":"Yang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinda","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mujun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"43901_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2165\/00003495-200666050-00005","volume":"66","author":"HG Kopp","year":"2006","unstructured":"Kopp, H. G. et al. Advances in the treatment of testicular cancer. Drugs 66, 641\u2013659. https:\/\/doi.org\/10.2165\/00003495-200666050-00005 (2006).","journal-title":"Drugs"},{"key":"43901_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J Clin"},{"key":"43901_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.eururo.2019.07.002","volume":"76","author":"JK Gurney","year":"2019","unstructured":"Gurney, J. K. et al. International trends in the incidence of testicular cancer: Lessons from 35 years and 41 countries. Eur. Urol. 76, 615\u2013623. https:\/\/doi.org\/10.1016\/j.eururo.2019.07.002 (2019).","journal-title":"Eur. Urol."},{"key":"43901_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ctrv.2009.05.004","volume":"35","author":"K Pliarchopoulou","year":"2009","unstructured":"Pliarchopoulou, K. & Pectasides, D. First-line chemotherapy of non-seminomatous germ cell tumors(NSGCTs). Cancer Treat. Rev. 35, 563\u2013569. https:\/\/doi.org\/10.1016\/j.ctrv.2009.05.004 (2009).","journal-title":"Cancer Treat. Rev."},{"key":"43901_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/14737140.2020.1736566","volume":"20","author":"P Chieffi","year":"2020","unstructured":"Chieffi, P., De Martino, M. & Esposito, F. Further insights into testicular germ cell tumor oncogenesis: Potential therapeutic targets. Expert Rev. Anticancer Ther. 20, 189\u2013195. https:\/\/doi.org\/10.1080\/14737140.2020.1736566 (2020).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"43901_CR6","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/jco.20.03292","volume":"39","author":"J Beyer","year":"2021","unstructured":"Beyer, J. et al. Survival and new prognosticators in metastatic seminoma: Results from the IGCCCG-Update Consortium. J. Clin. Oncol. 39, 1553\u20131562. https:\/\/doi.org\/10.1200\/jco.20.03292 (2021).","journal-title":"J. Clin. Oncol."},{"key":"43901_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/jama.2024.27122","volume":"333","author":"N Singla","year":"2025","unstructured":"Singla, N., Bagrodia, A., Baraban, E., Fankhauser, C. D. & Ged, Y. M. A. Testicular germ cell tumors: A review. JAMA 333, 793\u2013803. https:\/\/doi.org\/10.1001\/jama.2024.27122 (2025).","journal-title":"JAMA"},{"key":"43901_CR8","doi-asserted-by":"publisher","first-page":"102054","DOI":"10.1016\/j.ctrv.2020.102054","volume":"88","author":"G de Vries","year":"2020","unstructured":"de Vries, G., Rosas-Plaza, X., van Vugt, M., Gietema, J. A. & de Jong, S. Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities. Cancer Treat. Rev. 88, 102054. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102054 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"43901_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jama.299.6.672","volume":"299","author":"DR Feldman","year":"2008","unstructured":"Feldman, D. R., Bosl, G. J., Sheinfeld, J. & Motzer, R. J. Medical treatment of advanced testicular cancer. JAMA 299, 672\u2013684. https:\/\/doi.org\/10.1001\/jama.299.6.672 (2008).","journal-title":"JAMA"},{"key":"43901_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/jco.2006.07.7271","volume":"25","author":"LH Einhorn","year":"2007","unstructured":"Einhorn, L. H., Brames, M. J., Juliar, B. & Williams, S. D. Phase II study of Paclitaxel plus Gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J. Clin. Oncol. 25, 513\u2013516. https:\/\/doi.org\/10.1200\/jco.2006.07.7271 (2007).","journal-title":"J. Clin. Oncol."},{"key":"43901_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010006","author":"J Lobo","year":"2018","unstructured":"Lobo, J., Henrique, R. & Jer\u00f3nimo, C. The role of DNA\/Histone modifying enzymes and chromatin remodeling complexes in testicular germ cell tumors. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers11010006 (2018).","journal-title":"Cancers (Basel)"},{"key":"43901_CR12","doi-asserted-by":"publisher","first-page":"861995","DOI":"10.3389\/fcell.2022.861995","volume":"10","author":"AT Nicu","year":"2022","unstructured":"Nicu, A. T., Medar, C., Chifiriuc, M. C., Pircalabioru, G., Burlibasa, L. & G. & Epigenetics and Testicular Cancer: Bridging the Gap Between Fundamental Biology and Patient Care. Front. Cell. Dev. Biol. 10, 861995. https:\/\/doi.org\/10.3389\/fcell.2022.861995 (2022).","journal-title":"Front. Cell. Dev. Biol."},{"key":"43901_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00345-009-0498-6","volume":"28","author":"S Hinz","year":"2010","unstructured":"Hinz, S. et al. Deregulation of EZH2 expression in human spermatogenic disorders and testicular germ cell tumors. World J. Urol. 28, 631\u2013635. https:\/\/doi.org\/10.1007\/s00345-009-0498-6 (2010).","journal-title":"World J. Urol."},{"key":"43901_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/hep.22072","volume":"47","author":"NF Ma","year":"2008","unstructured":"Ma, N. F. et al. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. Hepatology 47, 503\u2013510. https:\/\/doi.org\/10.1002\/hep.22072 (2008).","journal-title":"Hepatology"},{"key":"43901_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.mrfmmm.2006.07.012","volume":"618","author":"CG Marfella","year":"2007","unstructured":"Marfella, C. G. & Imbalzano, A. N. The Chd family of chromatin remodelers. Mutat. Res. 618, 30\u201340. https:\/\/doi.org\/10.1016\/j.mrfmmm.2006.07.012 (2007).","journal-title":"Mutat. Res."},{"key":"43901_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/1471-2407-12-437","volume":"12","author":"WP He","year":"2012","unstructured":"He, W. P. et al. CHD1L protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival. BMC Cancer. 12, 437. https:\/\/doi.org\/10.1186\/1471-2407-12-437 (2012).","journal-title":"BMC Cancer"},{"key":"43901_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jss.2013.05.008","volume":"185","author":"X Ji","year":"2013","unstructured":"Ji, X. et al. CHD1L promotes tumor progression and predicts survival in colorectal carcinoma. J. Surg. Res. 185, 84\u201391. https:\/\/doi.org\/10.1016\/j.jss.2013.05.008 (2013).","journal-title":"J. Surg. Res."},{"key":"43901_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3892\/or.2019.7174","volume":"42","author":"S Li","year":"2019","unstructured":"Li, S. et al. CHD1L is associated with poor survival and promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma. Oncol. Rep. 42, 657\u2013669. https:\/\/doi.org\/10.3892\/or.2019.7174 (2019).","journal-title":"Oncol. Rep."},{"key":"43901_CR19","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.3892\/etm.2014.2017","volume":"8","author":"FR Su","year":"2014","unstructured":"Su, F. R., Ding, J. H., Bo, L. & Liu, X. G. Chromodomain helicase\/ATPase DNA binding protein 1-like protein expression predicts poor prognosis in nasopharyngeal carcinoma. Exp. Ther. Med. 8, 1745\u20131750. https:\/\/doi.org\/10.3892\/etm.2014.2017 (2014).","journal-title":"Exp. Ther. Med."},{"key":"43901_CR20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12094-013-1136-8","volume":"16","author":"Z Su","year":"2014","unstructured":"Su, Z. et al. CHD1L is a novel independent prognostic factor for gastric cancer. Clin. Transl. Oncol. 16, 702\u2013707. https:\/\/doi.org\/10.1007\/s12094-013-1136-8 (2014).","journal-title":"Clin. Transl. Oncol."},{"key":"43901_CR21","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1007\/s13277-013-0951-4","volume":"34","author":"F Tian","year":"2013","unstructured":"Tian, F. et al. Expression of CHD1L in bladder cancer and its influence on prognosis and survival. Tumour Biol. 34, 3687\u20133690. https:\/\/doi.org\/10.1007\/s13277-013-0951-4 (2013).","journal-title":"Tumour Biol."},{"key":"43901_CR22","doi-asserted-by":"publisher","first-page":"e98673","DOI":"10.1371\/journal.pone.0098673","volume":"9","author":"J Wu","year":"2014","unstructured":"Wu, J. et al. Presence of CHD1L over-expression is associated with aggressive tumor biology and is a novel prognostic biomarker for patient survival in human breast cancer. PLoS One. 9, e98673. https:\/\/doi.org\/10.1371\/journal.pone.0098673 (2014).","journal-title":"PLoS One"},{"key":"43901_CR23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41420-021-00682-y","volume":"7","author":"H Yan","year":"2021","unstructured":"Yan, H., Zhu, L., Zhang, J. & Lin, Z. Histone demethylase KDM4D inhibition suppresses renal cancer progression and angiogenesis through JAG1 signaling. Cell. Death Discov. 7, 284. https:\/\/doi.org\/10.1038\/s41420-021-00682-y (2021).","journal-title":"Cell. Death Discov"},{"key":"43901_CR24","doi-asserted-by":"publisher","first-page":"D545","DOI":"10.1093\/nar\/gkaa970","volume":"49","author":"M Kanehisa","year":"2021","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M. & Tanabe, M. KEGG: Integrating viruses and cellular organisms. Nucleic Acids Res. 49, D545-d551. https:\/\/doi.org\/10.1093\/nar\/gkaa970 (2021).","journal-title":"Nucleic Acids Res."},{"key":"43901_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"43901_CR26","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1002\/ijc.28610","volume":"134","author":"G Chappell","year":"2014","unstructured":"Chappell, G. et al. Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice. Int. J. Cancer 134, 2778\u20132788. https:\/\/doi.org\/10.1002\/ijc.28610 (2014).","journal-title":"Int. J. Cancer"},{"key":"43901_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13148-019-0644-y","volume":"11","author":"J Torrano","year":"2019","unstructured":"Torrano, J., Al Emran, A., Hammerlindl, H. & Schaider, H. Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming. Clin. Epigenetics. 11, 43. https:\/\/doi.org\/10.1186\/s13148-019-0644-y (2019).","journal-title":"Clin. Epigenetics"},{"key":"43901_CR28","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1038\/s41467-020-17227-z","volume":"11","author":"W Cao","year":"2020","unstructured":"Cao, W. et al. Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. Nat. Commun. 11, 3675. https:\/\/doi.org\/10.1038\/s41467-020-17227-z (2020).","journal-title":"Nat. Commun."},{"key":"43901_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-018-0861-6","volume":"17","author":"F Hu","year":"2018","unstructured":"Hu, F. et al. Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1\u03b2\/VEGFA signalling. Mol. Cancer 17, 107. https:\/\/doi.org\/10.1186\/s12943-018-0861-6 (2018).","journal-title":"Mol. Cancer"},{"key":"43901_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073490","author":"J Korbecki","year":"2021","unstructured":"Korbecki, J. et al. The role of CXCL16 in the pathogenesis of cancer and other diseases. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22073490 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"43901_CR31","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/glia.20651","volume":"56","author":"J Held-Feindt","year":"2008","unstructured":"Held-Feindt, J. et al. Overexpression of CXCL16 and its receptor CXCR6\/Bonzo promotes growth of human schwannomas. Glia 56, 764\u2013774. https:\/\/doi.org\/10.1002\/glia.20651 (2008).","journal-title":"Glia"},{"key":"43901_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cellimm.2016.11.001","volume":"311","author":"Y Ma","year":"2017","unstructured":"Ma, Y., Xu, X. & Luo, M. CXCR6 promotes tumor cell proliferation and metastasis in osteosarcoma through the Akt pathway. Cell. Immunol. 311, 80\u201385. https:\/\/doi.org\/10.1016\/j.cellimm.2016.11.001 (2017).","journal-title":"Cell. Immunol."},{"key":"43901_CR33","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1172\/jci40665","volume":"120","author":"L Chen","year":"2010","unstructured":"Chen, L. et al. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J. Clin. Invest. 120, 1178\u20131191. https:\/\/doi.org\/10.1172\/jci40665 (2010).","journal-title":"J. Clin. Invest."},{"key":"43901_CR34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13578-023-01113-4","volume":"13","author":"H He","year":"2023","unstructured":"He, H. et al. The SIRT7-mediated deacetylation of CHD1L amplifies HIF-2\u03b1-dependent signal that drives renal cell carcinoma progression and sunitinib resistance. Cell. Biosci. 13, 166. https:\/\/doi.org\/10.1186\/s13578-023-01113-4 (2023).","journal-title":"Cell. Biosci."},{"key":"43901_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1530\/erc-15-0196","volume":"23","author":"SW Cho","year":"2016","unstructured":"Cho, S. W. et al. CXCL16 signaling mediated macrophage effects on tumor invasion of papillary thyroid carcinoma. Endocr. Relat. Cancer 23, 113\u2013124. https:\/\/doi.org\/10.1530\/erc-15-0196 (2016).","journal-title":"Endocr. Relat. Cancer"},{"key":"43901_CR36","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.prp.2018.07.009","volume":"214","author":"L Hong","year":"2018","unstructured":"Hong, L., Wang, S., Li, W., Wu, D. & Chen, W. Tumor-associated macrophages promote the metastasis of ovarian carcinoma cells by enhancing CXCL16\/CXCR6 expression. Pathol. Res. Pract. 214, 1345\u20131351. https:\/\/doi.org\/10.1016\/j.prp.2018.07.009 (2018).","journal-title":"Pathol. Res. Pract."},{"key":"43901_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143568","author":"H Mir","year":"2021","unstructured":"Mir, H. et al. CXCR6-CXCL16 axis promotes breast cancer by inducing oncogenic signaling. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13143568 (2021).","journal-title":"Cancers (Basel)"},{"key":"43901_CR38","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.3892\/or.2015.4520","volume":"35","author":"X Yu","year":"2016","unstructured":"Yu, X. et al. CXCL16 induces angiogenesis in autocrine signaling pathway involving hypoxia-inducible factor 1\u03b1 in human umbilical vein endothelial cells. Oncol. Rep. 35, 1557\u20131565. https:\/\/doi.org\/10.3892\/or.2015.4520 (2016).","journal-title":"Oncol. Rep."},{"key":"43901_CR39","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1177\/039463201402700411","volume":"27","author":"JM Xu","year":"2014","unstructured":"Xu, J. M. et al. Blockade of the CXCR6 signaling inhibits growth and invasion of hepatocellular carcinoma cells through inhibition of the VEGF expression. Int. J. Immunopathol. Pharmacol. 27, 553\u2013561. https:\/\/doi.org\/10.1177\/039463201402700411 (2014).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"43901_CR40","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1681\/asn.2010080881","volume":"22","author":"G Chen","year":"2011","unstructured":"Chen, G. et al. CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis. J. Am. Soc. Nephrol. 22, 1876\u20131886. https:\/\/doi.org\/10.1681\/asn.2010080881 (2011).","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43901-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43901-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43901-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:06:41Z","timestamp":1777590401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43901-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43901"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43901-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Testicular cancer tissues and normal tissues were obtained from patients who underwent surgical resection at Renji Hospital, School of Medicine, Shanghai Jiao Tong University. Informed consents were signed by patients before this study. All experiments including animal studies were approved by the Ethics Committee of Renji Hospital (KY2020-193).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"13955"}}